Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction

NCT00113113 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00113113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00113113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2001
Completion date
Not reported
Enrollment
54 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

tumors